4 transcripts
MLYS
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
, an open-label extension trial called Transform-HTN to capture long-term safety and efficacy data and the proof-of-concept trial, Explore-CKD, evaluating
MLYS
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
to capture long-term safety and efficacy data and the proof-of-concept trial Explore-CKD evaluating lorundrostat in hypertensive CKD subjects.
Advance-HTN
MLYS
Earnings call transcript
NASDAQ
2023 Q4
21 Mar 24
an unbiased artificial intelligence model to expand the repertoire of useful tools for targeting lorundrostat to individuals most likely to drive long-term clinical
MLYS
Earnings call transcript
NASDAQ
2023 Q2
7 Aug 23
will contribute to our long-term safety data set.
Last month, we then announced the expansion of our clinical development of lorundrostat is a potential therapy
- Prev
- 1
- Next